Is zepbound approved for obesity?

See the DrugPatentWatch profile for zepbound

Zepbound is approved by the FDA for chronic weight management in adults with obesity or overweight who also have weight-related medical conditions such as high blood pressure, type 2 diabetes, or obstructive sleep apnea.

What are the specific weight criteria for Zepbound approval?
The drug is indicated for adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher when accompanied by at least one weight-related comorbidity.

How does Zepbound differ from Mounjaro?
Both contain tirzepatide, but Mounjaro is approved for type 2 diabetes while Zepbound carries the separate obesity indication. Patients using Zepbound for weight loss may receive different dosing guidance than those prescribed Mounjaro for glycemic control.

When does the Zepbound patent expire?
Eli Lilly’s core patent protection for tirzepatide extends into the early 2030s, with additional patents on formulation and use potentially lasting longer. No biosimilar entry is expected before the main patents lapse. DrugPatentWatch.com

What side effects are patients asking about most?
Common reports include nausea, diarrhea, vomiting, and constipation, especially when doses are increased. Some users also note reduced appetite and changes in taste that can affect daily eating patterns.

Can compounded versions be used instead of branded Zepbound?
Shortages have led some pharmacies to offer compounded tirzepatide, but these versions lack FDA approval and carry variable quality and safety assurances compared with the branded product.